At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 142 enrolled
Drug / intervention
TRS01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
In Brief
A Phase 3 clinical trial evaluating TRS01 and FDA approved steroid eye drop (masked) for Non-infectious Anterior Uveitis and Uveitic Glaucoma. Completed, enrolled 142 participants across 30 sites in 3 countries.
Detailed Summary
The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-infectious Anterior Uveitis, Uveitic Glaucoma
CountriesFrance, Germany, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartSep 2021
Primary CompletionJun 2023
TodayJul 2026
First PostedSep 13, 2021
Enrollment StartSep 20, 2021
Primary CompletionJun 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.8 years ago
Interventions
TRS01drug
TRS01 eye drops Dosed four times a day (QID)
FDA approved steroid eye drop (masked)drug
FDA approved steroid eye drop Dosed four times a day (QID)